Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, multicenter, open-label, dose-escalation study designed to estimate the
maximum tolerated dose (MTD) and determine the recommended Phase 2 dose (RP2D) of ADXS31-164.
Once the RP2D has been selected, up to 4 expansion cohorts will be evaluated.